Clinical Trial Update: Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of endocrine therapy plus OSI-906 with or without erlotinib for hormone-sensitive metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• OSI-906 (OSI-906)
• Tarceva (erlotinib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN